Drug Trial Radar · NCT00822614
Safety of Fentanyl TAIFUN Treatment
Last checked: Nov 19, 2026Latest source record: Jan 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Dec 2008
Primary completion
Dec 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- Akela Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy
Conditions
- Breakthrough Cancer Pain
Interventions
Fentanyl TAIFUNDrug
Inhalation of Fentanyl via TAIFUN inhaler
OpioidDrug
Current optimized BTP treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- AE ProfileTime frame: 28 Days
- To characterize the safety of Fentanyl TAIFUN treatment vs. the current BTP treatment based on the AE profileTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NZOZ
Włocławek, Wolnosc, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.